Introduction {#Sec1}
============

Retinoblastoma is the most common primary intraocular malignancy of childhood \[[@CR1]\]. Mutational inactivation of both alleles of the *RB1* tumor suppressor gene in the developing retina initiates the formation of retinoblastoma \[[@CR2], [@CR3]\]. The *RB1* gene consists of 27 exons and is located on chromosome 13q14 (GenBank accession number L11910, MIM\#180200). The gene encodes a ubiquitously expressed nuclear protein, which is involved in cell cycle regulation, cellular differentiation and survival \[[@CR4]\]. About 40% of retinoblastoma patients have a hereditary predisposition, caused by a heterozygous germline mutation in the *RB1* gene and are usually bilaterally affected \[[@CR5]\]. Over 600 different pathogenic mutations have been described. Patients with nonhereditary retinoblastoma only have one eye affected, no germline mutation in the *RB1* gene and two somatic retinal *RB1* mutations.

As is known from long-term follow-up studies \[[@CR6]--[@CR10]\], hereditary retinoblastoma subjects have a strongly increased risk for second primary malignancies, (including osteosarcoma, soft tissue sarcoma, melanoma and epithelial cancers) which is associated with excess mortality \[[@CR11]--[@CR13]\]. So far, it has not been examined in a large cohort of retinoblastoma patients whether specific *RB1* mutations might be associated with greater risk of second malignancy.

The objective of the present study was to investigate the *RB1* genotype in relation to second malignancy risk in hereditary retinoblastoma subjects.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

In the Netherlands we have data available of Dutch retinoblastoma subjects diagnosed from 1862 onwards. Detailed information on data collection and follow-up has been described previously \[[@CR9]\]. Relevant data collected for the present study were family history of retinoblastoma, tumor laterality, treatment for retinoblastoma, reports on invasive cancers, and date and (underlying) cause of death. Only the first cancer after retinoblastoma was included in this study. Time at risk for a second primary cancer began at diagnosis of retinoblastoma and ended on the date of second malignancy diagnosis, emigration, the date last known to be alive, the date of death, or the closing date of the study, whichever came first.

Patients with bilateral disease, a positive family history of retinoblastoma, or a germline mutation in the *RB1* gene detected by chromosomal or DNA analysis were classified as hereditary. The remaining patients, those with unilateral retinoblastoma, no family history of retinoblastoma, and no germline mutation detected in the *RB1* gene, were classified as having non-hereditary retinoblastoma.

Eligible subjects for the current study included all hereditary retinoblastoma patients from the Dutch retinoblastoma cohort (1862--2005), in whom a germline *RB1* mutation was documented. If a retinoblastoma patient had died before DNA-testing could be performed, but a *RB1* mutation was determined in the family, the patient was considered to be a carrier of the familial mutation (*n* = 26). Every affected family member was handled as a single case in the analysis. Of the 1,028 retinoblastoma patients in the Dutch cohort, we identified a total of 410 (39.9%) hereditary cases. Two-hundred eleven patients were excluded because no DNA analysis could be performed (*n* = 180) or DNA analysis did not detect a *RB1* mutation (*n* = 31). The remaining 199 patients were included in this study (see Fig. [1](#Fig1){ref-type="fig"}), of whom 168 were alive at the time of inclusion.Fig. 1Flow chart showing reasons for inclusion and exclusion of retinoblastoma patients with hereditary retinoblastoma from our cohort. In the total group of 410 hereditary retinoblastoma patients from our cohort, 99 primary tumors (SPT) have been diagnosed. In the flow chart is also depicted in which in- or excluded group these SPT's have occurred. Percentage is calculated from the total of 99 SPT's

This study was approved by the Medical Ethics Committees of all participating hospitals, and was conducted in accordance with the principles of the Helsinki declaration.

Mutation screening {#Sec4}
------------------

Since the beginning of the 1990s all newly diagnosed retinoblastoma patients in the Netherlands undergo germline *RB1* mutation analysis. Many patients who were diagnosed before that time underwent DNA-testing between 1990 and 2005, when they were referred to the clinical genetics department (*n* = 90). Rb patients diagnosed prior to 1990, in whom mutation testing had not yet been performed at the time of the study and who wanted to participate in the study, were invited to undergo DNA-testing and were offered genetic counseling (*n* = 23).

DNA analysis included direct sequencing of exons 1 and 15, and the *RB1* promoter and Denaturing Gradient Gel Electrophoresis (DGGE) analysis of the other exons and flanking intronic sequences. To detect large deletions and duplications Multiplex Ligation-dependent Probe Amplification (MLPA) analysis was performed. If warranted, e.g. when dysmorphic features or mental retardation was noted, karyotyping was performed to detect chromosomal rearrangements. With these techniques we have been able to detect 90% of mutations in familial and/or bilateral cases.

Type of *RB1* mutation {#Sec5}
----------------------

In the *RB1* gene are several methylated CGA codons known to lead to 11 recurrent nonsense mutations by C\>T transitions \[[@CR14]--[@CR16]\]. An important factor in the high recurrence of mutations at these sites was shown to be deamination of 5-methylcytosine \[[@CR17]\].

For this study mutations in the promoter, exon 1, missense mutations and deletions of the complete *RB1* gene were regarded as low penetrance mutations, based on previous studies \[[@CR18]--[@CR21]\]. Four out of six familial splice mutations were also regarded as low penetrance mutations, based on a diseased eye ratio (DER) of ≤1.5, defined as the total number of affected eyes per family divided by the number of mutation carriers in the family \[[@CR22], [@CR23]\]. To exclude possible mosaicism as a cause of milder expression the first mutation carrier in these families was excluded from the analysis.

Statistical methods {#Sec6}
-------------------

We compared the frequency of second primary cancers among hereditary retinoblastoma survivors with specific documented *RB1* mutations, and tested for differences using Chi-square tests.

Multivariate Cox regression analysis was performed to quantify the effects of specific *RB1* mutations on the risk of second primary malignancies. Therapy, age, laterality, sex, and familial or sporadic occurrence were taken into account as possible confounders (SPSS, Chicago, IL).

Results {#Sec7}
=======

Median age of all patients included in the study cohort was 30.0 years (range 1.0--75.0). Of the total of 199 participants, 111 were familial cases and 88 concerned sporadic patients. After a median follow-up time of 30.2 years (range 1.33--76.0), 44 carriers of a *RB1* mutation from 31 different families developed a second primary malignancy. Table [1](#Tab1){ref-type="table"} shows the number of germline *RB1* mutations according to type of mutation and lists the number of second primary tumors according to type of mutation. The mutations found in patients who developed a second malignancy were distributed throughout most of the *RB1* gene and did not appear to cluster in one region (Fig. [2](#Fig2){ref-type="fig"}). There was no correlation between the different types of second malignancies diagnosed in these patients and the type of mutation or the region of the gene where the mutation was located. In the group of retinoblastoma survivors who developed a second malignancy, only nonsense and frameshift mutations, certain splice mutations and large rearrangements were observed.Table 1Number and type of second primary tumor (SPT) by mutation typeType of *RB1* mutation^a^Number of carriers\
*n* (%)^a^Number of cases with SPT\
*n* (%)^b^Type of SPTSarcoma^c^MelanomaEpithelial cancerOther^d^Nonsense/frameshift mutation117 (58.8)31 (26.5)11810*2* *Recurrent nonsense mutation49 (41.9)17 (34.7)7721* *Low penetrance mutation* = *exon 17 (6)1 (14.3)*Splice mutation34 (17.1)7 (20.6)2140 *Low penetrance mutation11 (32.4)0*Large rearrangements35 (17.6)6 (17.1)2220 *Low penetrance mutation21 (60)1 (4.8)1*Missense mutation11 (5.5)00000 *Low penetrance mutation11 (100)0*Promoter mutation2 (1)00000 *Low penetrance mutation2 (100)0*Total19944 (22.1)1511162^a^ Subclassification of the mutation type is shown in italics, percentage as compared to total number of cases with this mutation type^b^ Percentage of cases with an SPT as compared to total number of cases with this mutation type^c^ Including soft tissue sarcoma, osteosarcoma, and chondrosarcoma^d^ Malignant tumor not otherwise specified and brain tumorFig. 2Graphical representation of *RB1* and mutations found among hereditary retinoblastoma subjects diagnosed with a second primary malignancy (*n* = 44). Exons 1 through 27 are not drawn to scale. Every symbol represents a retinoblastoma subject diagnosed with a second primary malignancy. *Black* symbols represent sporadic hereditary retinoblastoma subjects. *Greyscale* coloured symbols represent subjects with familial retinoblastoma. *Downward-pointing* symbols represent mutations in exons, and *upward-pointing* symbols represent mutations in introns. The *horizontal lines* below depict large rearrangements

Table [2](#Tab2){ref-type="table"} displays the mutations of all patients who developed a second primary malignancy, along with clinical details, listed according to subcategories of germline *RB1* mutation type.Table 2Descriptions of retinoblastoma patients with a second primary malignancy according to subcategories of *RB1* mutation typeSubject\
no.^a,b^Family^c^Number of RB patients in the family without second primary malignancy (age at inclusion)SiteMutation description^d^ProteinLateralityFirst in familyTherapyType of second primary malignancy^e^Second primary malignancy (age at diagnosis)Nonsense or frameshift mutation 1F22NAExon 1g.2121dupCp.Ala22GlyfsX9BilYesRTEpithelialB (59) 2F111 (37)Exon 2g.5446G\>Tp.Glu54XBilYesEnuclEpithelialBl (52) 3F121 (12)Exon 2g.5505_5506dupp.Ala74GlufsX4BilYesRT + CH[Other]{.ul}(44) 4F164 (59, 40, 14, 6)Exon 6g.45855delTp.Leu199TyrfsX2BilNoRT[Osteosarcoma]{.ul}(5) 5^a^F31NAExon 8g.59695C\>Tp.Arg255XBilYesRT[Osteosarcoma]{.ul}(12) 6F172 (4^f^, 29)Exon 8g.59702_59703dupp.Asn258ArgfsX7UlYesEnuclEpithelialPa (56) *7F17Exon8g.59702_59703dupp.Asn258ArgfsX7BilNoRTEpithelialBl (51)* *8F17Exon8g.59702_59703dupp.Asn258ArgfsX7BilNoRT* + *CHEpithelialL (39)* 9^a^F40Exon 10g.64348C\>Tp.Arg320XBilYesEnuclEpithelialC (49) *10*^a^*F4Exon 10g.64348C*\>*Tp.Arg320XBilNoRTMelanoma(25)* 11^a^F52 (26, 1^f^)Exon 11g.65386C\>Tp.Arg358XBilYesRT + CHSarcomaLMS (41) 12F62 (47, 41)Exon 12g.70261C\>Tp.Gln383XUlYesEnuclEpithelialBl (62) 13^a^F83 (26, 11, 49)Exon 14g.76430C\>Tp.Arg445XBilYesEnuclEpithelialL (65) *14*^a^*F8Exon 14g.76430C*\>*Tp.Arg445XBilNoEnuclMelanoma(23)* *15*^a^*F8Exon 14g.76430C*\>*Tp.Arg445XBilNoRTMelanoma(37)* *16*^a^*F8Exon 14g.76430C*\>*Tp.Arg445XBilNoRTMelanoma(45)* *17*^a^*F8Exon 14g.76430C*\>*Tp.Arg445XBilNoRTMelanoma(21)* 18^a^F23NAExon 15g.76898C\>Tp.Arg467XBilNoRT + CHMelanoma(28) 19^a^F91 (54)Exon 17g.78238C\>Tp.Arg552XBilYesRTSarcomaLMS (33) *20*^a^*F9Exon 17g.78238C*\>*Tp.Arg552XBilNoRT* + *CHOsteosarcoma(12)* 21^a^F100Exon 18g.150037C\>Tp.Arg579XUlYesMissingOther(59) *22*^a^*F10Exon 18g.150037C*\>*Tp.Arg579XBilNoRTMelanoma(35)* 23^a^F24NAExon 18g.150037C\>Tp.Arg579XBilNoRT[Osteosarcoma]{.ul}(10) 24F25NAExon 19g.153211T\>Ap.Tyr606XBilNoRT[Melanoma]{.ul}(35) 25F133 (42^f^, 70, 51)Exon 20g.156787_156788\
delGCp.Thr687ProfsX4BilNoEnuclEpithelialO (72) *26F13Exon 20g.156787_156788*\
*delGCp.Thr687ProfsX4UlNoEnuclSarcomaUnknown location (50)* 27F142 (53, 50)Exon 21g.160832G\>Tp.Glu737XUlYesEnuclEpithelialO (58) *28F14Exon 21g.160832G*\>*Tp.Glu737XBilNoRTOsteosarcoma(20)* 29^a^F27NAExon 23g.162237C\>Tp.Arg787XBilNoRT + CHSarcomaLMS (32) 30^a^F28NAExon 23g.162237C\>Tp.Arg787XBilNoRTSarcomaLipo (12) 31F26NAExon 23g.162266delCp.Leu797TyrfsX13BilNoRT + CHOsteosarcoma(26)Splice mutation 32F71 (29)Exon 13g.73869G\>Ap.Gln444Gln\
exon 13 skippedBilYesRTEpithelialL (48) 33F20NAIntron 6g.45867G\>A/\
IVS6 + 1G\>An.i.BilNoRTEpithelialB (57) 34F21NAIntron 14g.76491G\>T/\
IVS14 + 5G\>Tn.i.BilNoRTMelanoma(51) 35F19NAIntron 17g.149997G\>A/\
IVS17 − 1G\>An.i.BilNoRT[Sarcoma]{.ul}Rhab (8) 36F10Intron 20g.160729G\>C/\
IVS20 − 1G\>Cn.i.BilYesRTEpithelialBl (62) *37F1Intron 20g.160729G*\>*C/*\
*IVS20* − *1G*\>*Cn.i.BilNoRT[Sarcoma]{.ul}His (31)* *38F1Intron 20g.160729G*\>*C/*\
*IVS20* − *1G*\>*Cn.i.BilNoRTEpithelialB (43)*Large rearrangements 39F151 (5)Duplica- tion exon 3g.39446-?\_39561 + ?dupn.i.UlYesEnuclMelanoma(31) 40F32 (45, 9)Deletion\
*RB1*c.-138-?\_27841 + ?del--BilNoRT[Sarcoma]{.ul}Rhab (11) 41F22 (17, 15)Deletion exon 10/11Del exon 10 or 10 and 11n.i.BilYesRTMelanoma(31) 42F29NADeletion exon 3-17g.39446-?\_78279 + ?deln.i.BilNoRTSarcomaLMS (32) 43F30NADeletion exon 6-17g.45799-?\_78279 + ?deln.i.BilNoRT[Epithelial]{.ul}Seb (38) 44F182 (68, 42)Deletion exon\
9--27g.61730-?\_g177078 + ?deln.i.UlYesEnuclEpithelialC (57)*RB* retinoblastoma, *NA* not applicable (*i.e.* sporadic retinoblastoma patient, *n.i.* not investigated), *Bil* bilateral disease, *Ul* unilateral disease, *RT* radiation therapy, *CH* chemotherapy, *Enucl* enucleation*B* breast cancer, *Bl* bladder cancer, *Pa* pancreatic cancer, *L* lung cancer, *C* colon cancer, *LMS* leiomyosarcoma, *O* ovarian cancer, *Lipo* liposarcoma, *Rhab* rhabdomyosarcoma, *His* histiocytoma, *Seb* sebaceous adenocarcinoma^a^ Carriers of a recurrent stop mutation^b^ Italicized cases represent family members also affected with a second primary malignancy^c^ Family numbers 1--18: have more affected family members with RB; family numbers 19--31: sporadic retinoblastoma patients^d^ Reference sequence GenBank \#L11910^e^ Underlined types of second primary malignancies represent tumours diagnosed inside the field of radiation; defined as tumor in the eye lids, orbits, periocular sinuses, temporal bones, or skin overlying the temporal bone region^f^ Died of other cause than second primary cancer

We assessed the risk of second malignancy in relation to type of mutation by multivariable Cox model analysis, adjusted for age and therapy. This showed that subjects carrying one of the recurrent nonsense mutations had a significantly elevated risk of developing second malignancies, compared to subjects carrying other mutations (hazard ratio \[HR\], 3.53; \[95% confidence interval (CI), 1.82--6.84\]; *P* = .000). Since 5 members of family 8 developed a second malignancy, we did the same analysis while excluding this family. This did not significantly change the outcome (HR, 3.17; \[95% CI, 1.50--6.69\]; *P* = .002). Leaving both family 8 and all low penetrance mutations out of the analysis, showed a lower but still statistically significantly increased risk for recurrent nonsense mutations as compared to other mutations (HR, 2.46; \[95% CI, 1.14--5.28\]; *P* = .02).

Table [3](#Tab3){ref-type="table"} shows the recurrent nonsense mutations known in the *RB1* gene, and displays which of these mutations are found in our cohort in relation to the number of patients and the number of second primary cancers in these patients.Table 3List of the 11 recurrent *RB1* nonsense mutations, the number of patients in our cohort carrying the mutation and the number of patients with this mutation who developed a second primary tumor (SPT)ExonMutationProteinNumber of patients in our cohortNumber of patients who developed a SPT8g.59683C\>TArg.251X208g.59695C\>TArg.255X1110g.64348C\>TArg.320X5211g.65386C\>TArg.358X3114g.76430C\>TArg.445X11514g.76460C\>TArg.455X8015g.76898C\>TArg.467X1117g.78238C\>TArg.552X3217g.78250C\>TArg.556X5018g.150037C\>TArg.579X7323g.162237C\>TArg.787X32Total4917

A statistically significantly decreased risk for a second primary malignancy was found in the 52 patients with a low penetrance mutation when compared to other mutations (HR, .19; \[95% CI, .05--.81\]; *P* = .025). Of all 34 patients carrying a splice mutation, eleven were carrier of a low penetrance mutation according to our definition, i.e. a DER ≤1.5. None of the carriers of a low penetrance splice mutation developed a second primary cancer. Out of 21 carriers of a deletion involving the whole *RB1* gene, just one developed a sarcoma and one out of seven carriers of a mutation in exon 1 developed breast cancer at the age of 59. No second malignancies were observed in carriers of a *RB1* promoter or missense mutation (n = 13).

Discussion {#Sec8}
==========

Our study is the first to examine the association between specific *RB1* germline mutations and the risk of second primary malignancies in a nationwide well-documented cohort. Adjusting for age and therapy, we found a higher second primary malignancy risk for retinoblastoma subjects carrying a recurrent nonsense mutation, and a lower risk for carriers of a low penetrance mutation.

We first compared the risk of second primary malignancies for carriers of recurrent nonsense mutations to all other mutations in the *RB1* gene. Because one family (F8) with many family members affected by a second malignancy may have influenced the outcome too much, we excluded this family from the analysis. This still showed a statistically significantly increased risk. It is remarkable that 4 members of this family developed a melanoma. This could be due to common genetic background, though this phenomenon does not hold true for other families. As far as we are aware, the family does not display any signs of dysplastic nevus syndrome. We further hypothesized that the increased risk of second malignancies for recurrent mutations compared to all other mutations may have been caused by a substantial contribution of the lower risk of second malignancies for low penetrance mutations, included in the comparison. Therefore we also left the low penetrance mutations out of the analysis. This still showed a significantly increased risk of second primary cancers for recurrent nonsense mutations. Three recurrent nonsense mutations did not demonstrate any second malignancies in our study cohort (Table [3](#Tab3){ref-type="table"}). Whether these mutations do not lead to a higher second malignancy risk, needs to be clarified in future studies.

What could be the cause of the higher risk for second malignancies in carriers of recurrent nonsense mutations? Nonsense and frameshift mutations are associated with bilateral retinoblastoma and high (\>90%) penetrance \[[@CR19]\], irrespective of the location of the premature stop mutation. This is attributed to nonsense mediated mRNA decay (NMD): a mechanism of mRNA surveillance that prevents the expression of truncated proteins, by breaking down mutant mRNA containing a premature termination codon \[[@CR24]\]. NMD can be beneficial, eliminating truncated transcripts that could lead to proteins with possible dominant negative or gain-of function effects, but may also be harmful when preventing translation of truncated protein that would otherwise still be partly functional \[[@CR25], [@CR26]\]. Studies have also shown that NMD efficacy may vary between tissues \[[@CR27], [@CR28]\]. An explanation for our findings could be that specific nonsense mutations escape NMD in certain tissues, which will result in the expression of a truncated protein. This truncated protein may either have residual activity resulting in a milder effect or may have a dominant negative effect, as has been described for other tumor-suppressor genes \[[@CR25], [@CR29]\]. The higher risk in recurrent nonsense mutation carriers may then be explained by a differential effect of NMD between these mutations and other truncating mutations. How such a differential effect would specifically exist between the two different types of truncating mutations remains to be determined. Alternatively, while the recurrent nonsense mutations result in the loss of a 5-methylcytosine within the gene, this may affect the chromatin structure and/or expression of the gene and thereby increasing the chance of transformation. However, in spite of a clearly elevated risk for recurrent nonsense mutations in our cohort, we cannot rule out that the elevated risk is a chance finding.

Genotype-phenotype correlations of *RB1* mutations have been described for specific types of mutations: certain splice mutations, promoter, exon 1 and missense mutations lead to reduced expressivity (unilateral retinoblastoma) and incomplete penetrance (unaffected carriers) of retinoblastoma \[[@CR18], [@CR19], [@CR21], [@CR23], [@CR30]\]. This is attributed to a reduction in the amount of normal protein that is produced or to residual activity of mutant protein \[[@CR18], [@CR19]\]. Reduced expressivity and incomplete penetrance have also been described for deletions of the complete *RB1* gene. This is thought to be caused by co-deletion of adjacent unknown genes leading to a greater chance of apoptosis, when the wildtype allele is lost as the second hit in the tumor \[[@CR20]\]. In line with reduced expressivity in the retina, we demonstrated a lower risk of second primary cancers for carriers of these low penetrance mutations. In our study group none of the carriers (*n* = 24) of a missense, promoter or low penetrance splice *RB1* mutation developed a second malignancy, and just one out of 7 carriers with a mutation in exon 1 developed another cancer, i.e. breast cancer at age 59. The latter may also be attributed to the high population risk of breast cancer. A lower risk for second primary malignancies was noted for carriers of a complete deletion of the *RB1* gene as well: only one out of 21 carriers developed a second malignancy (i.e. rhabdomyosarcoma at age 11).

Strength of our study is the unique large data set of genotyped survivors of retinoblastoma from a population based cohort. Very few studies on genotype-phenotype relations of *RB1* mutations mention second primary cancers. Two studies on mutations in de *RB1* gene stated that they could not detect an association between the mutation and manifestation of a second primary cancer or tumor type \[[@CR21], [@CR31]\]. These studies included only a few patients with second primary cancers, however. Some limitations of our study should be considered. First, our mutation detection rate was 90% for all familial and bilateral cases at the time of the study. Leaving 10% of hereditary patients out of the analysis may have influenced the outcome. Some mutations may have been missed, because they are present in a mosaic state; others because they might be located deep in an intron. Second, some types of mutations (e.g. promoter mutations) are relatively rare and therefore some mutation type subgroups were small, making it difficult to draw firm conclusions. A third limitation is that *RB1* mutation detection has become available just 20 years ago. Although many patients from the Dutch retinoblastoma cohort have been genotyped in the past years, this study still comprises a relatively young group of retinoblastoma subjects; almost 50% of all known patients with hereditary retinoblastoma could be included. Quite a few patients diagnosed with (osteo)sarcoma had already died before it was possible to perform DNA analysis. The exclusion of these (osteo)sarcomas may have limited our ability to detect possible associations between specific mutations and sarcoma risk.

In conclusion, our results suggest a genotype-phenotype correlation for second primary malignancies of retinoblastoma survivors and may impact on long-term surveillance protocols of patients with hereditary retinoblastoma, if confirmed by future studies.
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